Crit Pathw Cardiol. 2005 Sep;4(3):121-6.

The rate control, anticoagulation therapy, and electrophysiology/antiarrhythmic medication pathway for the management of atrial fibrillation and atrial flutter.

Source

Division of Cardiology, St. Luke's-Roosevelt Hospital, Columbia University College of Physicians and Surgeons, New York, New York 10025, USA. eherzog@chpnet.org

Abstract

Atrial fibrillation is the most common cardiac rhythm disturbance encountered in clinical practice. Recent guidelines for the management of atrial fibrillation are complex and do not include the management of atrial flutter.To bridge the gap between currently available guidelines and patient management, we have developed a unique, simple, yet comprehensive pathway for the management of atrial fibrillation and atrial flutter. The pathway has been designed with the acronym RACE (rate control, anticoagulation therapy, and electrophysiology/antiarrhythmic medication) to reflect the 3 main components in patient management.This model is designed to mandate and then markedly improve adherence to the published American College of Cardiology, the American Heart Association and the European Society of Cardiology guidelines.

PMID:: 18340196; [PubMed]

LinkOut - more resources

Full Text Sources

Supplemental Content

Related citations

ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. [Europace. 2006]
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.
Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, et al. Europace. 2006 Sep; 8(9):651-745.
[Atrial fibrillation: rate or rhythm control--individual patient management]. [Z Kardiol. 2005]
[Atrial fibrillation: rate or rhythm control--individual patient management].
Schwab JO, Lüderitz B. Z Kardiol. 2005; 94 Suppl 4:IV/49-52.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. [Circulation. 2006]
ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.
Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, et al. Circulation. 2006 Aug 15; 114(7):e257-354.
Review Key issues in the management of atrial fibrillation--protecting the patient and controlling the arrhythmia. [Scott Med J. 2007]
Review Key issues in the management of atrial fibrillation--protecting the patient and controlling the arrhythmia.
Jenkins SM, Dunn FG. Scott Med J. 2007 Aug; 52(3):27-35.
Review [Anticoagulation and atrial fibrillation]. [Medicina (B Aires). 2011]
Review [Anticoagulation and atrial fibrillation].
Prieto S, Young P, Ceresetto JM, Bullorsky EO. Medicina (B Aires). 2011; 71(3):274-82.

See reviews... See all...

Recent activity

Clear Turn Off Turn On

The rate control, anticoagulation therapy, and electrophysiology/antiarrhythmic ...
The rate control, anticoagulation therapy, and electrophysiology/antiarrhythmic medication pathway for the management of atrial fibrillation and atrial flutter.
Crit Pathw Cardiol. 2005 Sep ;4(3):121-6.

PubMed
Signals from the neural crest regulate beta-cell mass in the pancreas.
Signals from the neural crest regulate beta-cell mass in the pancreas.
Development. 2008 Jun ;135(12):2151-60.

PubMed
The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant t...
The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review.
Curr Opin Oncol. 2007 Nov ;19(6):564-72.

PubMed
How gluten-free is gluten-free, and what does this mean to coeliac patients?
How gluten-free is gluten-free, and what does this mean to coeliac patients?
Eur J Gastroenterol Hepatol. 2003 May ;15(5):461-3.

PubMed
Fetal aberrant right subclavian artery in normal and Down syndrome fetuses.
Fetal aberrant right subclavian artery in normal and Down syndrome fetuses.
Ultrasound Obstet Gynecol. 2008 Jan ;31(1):25-9.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to:

The rate control, anticoagulation therapy, and electrophysiology/antiarrhythmic medication pathway for the management of atrial fibrillation and atrial flutter.

Source

Abstract

LinkOut - more resources

Full Text Sources

Supplemental Content

Related citations

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information